Cellosaurus cell line HT-1080/hCLDN-2 (CVCL

Cellosaurus HT-1080/hCLDN-2 (CVCL_C3V8)

Cross-references
Cell line name	HT-1080/hCLDN-2
Synonyms	hCLDN-2/HT1080
Accession	CVCL_C3V8
Resource Identification Initiative	To cite this cell line use: HT-1080/hCLDN-2 (RRID:CVCL_C3V8)
Comments	Population: Caucasian. Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2041; CLDN2. Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo. Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
Sequence variations	Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line). Mutation; HGNC; HGNC:5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line). Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
Disease	Fibrosarcoma (NCIt: C3043) Fibrosarcoma (ORDO: Orphanet_2030)
Species of origin	Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy	Parent: CVCL_0317 (HT-1080)
Sex of cell	Male
Age at sampling	35Y
Category	Cancer cell line
Publications	PubMed=25118216; DOI=10.1124/jpet.114.216911 Li X.-R., Iida M., Tada M., Watari A., Kawahigashi Y., Kimura Y., Yamashita T., Ishii-Watabe A., Uno T., Fukasawa M., Kuniyasu H., Yagi K., Kondoh M. Development of an anti-claudin-3 and -4 bispecific monoclonal antibody for cancer diagnosis and therapy. J. Pharmacol. Exp. Ther. 351:206-213(2014) PubMed=27713828; DOI=10.1002/prp2.266; PMCID=PMC5045943 Hashimoto Y., Kawahigashi Y., Hata T., Li X.-R., Watari A., Tada M., Ishii-Watabe A., Okada Y., Doi T., Fukasawa M., Kuniyasu H., Yagi K., Kondoh M. Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody. Pharmacol. Res. Perspect. 4:e00266.1-e00266.14(2016)
Encyclopedic resources	Wikidata; Q116049507
Entry history
Entry creation	15-Dec-2022
Last entry update	19-Dec-2024
Version number	5